Intercept Pharmaceuticals

Intercept Pharmaceuticals is a company that develops commercial novel therapeutics to treat threatening diseases. The company was founded in 2002, in New York, New York, United States.

The company works to create treatments for diseases such as non-viral liver diseases, primary biliary cholanitis (PBC), non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. Severe forms of fatty liver disease, inflammation, cell damage, and progressive auto-immune diseases are at the forefront of Intercept Pharmaceuticals' treatments, therapeutic development, and the educational materials they offer.

Treatments for NASH include treatment of comorbidities, which can generally mean lifestyle changes for patients such as diet and exercise activities. In terms of a pharmacologic treatment, the company has investigational drugs that are ready for clinical trials. These drugs are meant to stabilize or even undo the effects of fibrosis that NASH can cause. The collection of investigational drugs Intercept is currently evaluating includes three potential treatments. Obeticholic acid (OCA), Regenerate, and Reverse are each undergoing Phase 3 clinical trials, and are awaiting approval by a regulatory authority.

Intercept is also working on treatments for PCB infections. Ocaliva, or obeticholic acid, is Intercept's primary treatment for PBC as it is designed to help patients with a high alkaline phosphatase level.